Low systemic exposure after repeated topical application of pimecrolimus (Elidel®, SDZ ASM 981) in patients with atopic dermatitis

Background. Pimecrolimus is a cell-selective inhibitor of inflammatory cytokine release developed specifically for the treatment of inflammatory skin diseases. Aim: The objective of this study was to evaluate blood concentrations and tolerability of pimecrolimus during topical treatment. Methods: Twelve adult patients with extensive atopic dermatitis were enrolled in an open-label, noncontrolled, pharmacokinetic study. The patients were treated twice daily for 3 weeks with pimecrolimus cream 1% on all lesions. Pimecrolimus blood concentrations were measured at regular time points, and the safety and tolerability were monitored throughout the study. Results: In 78% of the 444 blood samples evaluated, pinnecrolimus concentrations remained below the limit of quantitation (0.5 ng/ml). The highest concentration measured was 1.4 ng/ml. There was no indication of drug accumulation. Pimecrolimus was well tolerated locally and systemically. Conclusion:The 3-week twice daily treatment with pimecrolimus cream 1% results in consistently low pimecrolimus blood concentrations with no accumulation. Pimecrolimus cream appears suitable for the long-term management of atopic dermatitis. Copyright (C) 2002 S. Karger AG, Basel.